Blair William & Co. IL Has $1.27 Million Stock Holdings in argenex SE $ARGX

Blair William & Co. IL boosted its position in shares of argenex SE (NASDAQ:ARGX) by 11.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,310 shares of the company’s stock after buying an additional 231 shares during the quarter. Blair William & Co. IL’s holdings in argenex were worth $1,273,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Rakuten Securities Inc. increased its position in shares of argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company’s stock valued at $36,000 after buying an additional 22 shares in the last quarter. WPG Advisers LLC acquired a new stake in argenex in the 1st quarter valued at about $37,000. Golden State Wealth Management LLC acquired a new stake in argenex during the first quarter worth approximately $44,000. Brooklyn Investment Group lifted its position in argenex by 102.7% during the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after acquiring an additional 38 shares during the last quarter. Finally, Banque Transatlantique SA acquired a new stake in argenex during the first quarter worth approximately $62,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ARGX. Royal Bank Of Canada started coverage on shares of argenex in a report on Monday, August 25th. They set an “outperform” rating and a $850.00 target price on the stock. Guggenheim reiterated a “buy” rating and set a $1,070.00 price target on shares of argenex in a report on Thursday, September 18th. Zacks Research upgraded shares of argenex from a “hold” rating to a “strong-buy” rating in a report on Monday, September 22nd. Deutsche Bank Aktiengesellschaft lowered shares of argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. Finally, Wall Street Zen raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $817.53.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $815.61 on Thursday. argenex SE has a one year low of $510.05 and a one year high of $819.71. The company’s fifty day moving average price is $727.75 and its 200-day moving average price is $632.02. The firm has a market capitalization of $49.92 billion, a price-to-earnings ratio of 41.83, a PEG ratio of 0.87 and a beta of 0.46.

argenex (NASDAQ:ARGX) last released its earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, beating the consensus estimate of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The company had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million. As a group, equities research analysts expect that argenex SE will post 3.13 EPS for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.